Great News! A Kids’ Brain Tumor Cure (PLGA Foundation) Applauds Congressman Chuck Fleischmann (R-TN) for Efforts to Focus NIH Research on PLGA Brain Cancer. House Appropriations Member Cites Long-Term Impact of Brain Surgery, Chemo and Radiation on Children With PLGA. We are thrilled that our advocacy efforts have finally attracted the attention of Congress and the NIH in an exciting development on Capitol Hill on March 3, 2015.

A Kids’ Brain Tumor Cure (PLGA Foundation) today applauded Congressman Chuck Fleischmann (R-TN) for his questions regarding the status of research on Pediatric Low Grade Astrocytoma during a House Labor, Health and Education Appropriations Subcommittee hearing with Dr. Francis Collins, Director of the National Institutes of Health.  Congressman Fleischmann first learned of slow-growing PLGA cancer in a meeting with an eight year old boy who has been battling the cancer for the last five years.  This little boy shared with the Congressman how his battle against PLGA has impacted his life, including how the disease ruined his optic nerve leaving him completely blind.

“Congressman Fleischmann’s questions to NIH Director Francis Collins are shining a light on the need for an increased federal investment into research on this slow-growing terminal brain cancer,” said A.J. Janower, President of A Kids’ Brain Tumor Cure (PLGA Foundation).  “The Congressman’s efforts to re-focus the NIH research portfolio on slow-growing children’s brain cancer should give hope to the families battling PLGA.”

The Congressman noted how current treatments for PLGA brain cancer are invasive, highly toxic, and relatively ineffective.  He requested an update from NIH Director Collins on the current status of research and clinical trials at the NIH.  Director Collins noted that “PLGA is one of those pediatric cancers that we desperately need better answers for.”

“When a child battling PLGA cancer spends most of his or her life under these devastating medical regimes, the result is often long-term physical and cognitive disabilities,” said Janower.  “The PLGA Foundation will continue to invest funds into research on this devastating cancer, and we look forward to the opportunity to work cooperatively with the NIH on this research.”

We are thrilled that our advocacy efforts are reaching Congress and that the NIH is finally talking about this orphan disease.  Our hope is that the seed funding we provide to researchers to prove the efficacy of PLGA research projects will lay the necessary groundwork to enable these researchers to apply to the NIH/NCI for larger grant dollars.

To view Congressman Fleischmann’s remarks at the March 3, 2015 hearing, please click on the link below or visit this page.